
Alessandro Cozzi-Lepri

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5429879/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Transmitted HIVâ€1 drug resistance in a large international cohort using nextâ€generation sequencing: results from the Strategic Timing of Antiretroviral Treatment (START) study. HIV Medicine, 2021, 22, 360-371.	2.2	12
2	Signals were broadly positive for months, but never definitive: the tocilizumab story. Clinical Microbiology and Infection, 2021, , .	6.0	1
3	Epidemiology and Outcomes of Bloodstream Infections in HIV-Patients during a 13-Year Period. Microorganisms, 2020, 8, 1210.	3.6	6
4	Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatology, The, 2020, 2, e474-e484.	3.9	772
5	Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?. BMC Public Health, 2019, 19, 1291.	2.9	4
6	Evolution of major nonâ€HIVâ€related comorbidities in HIVâ€infected patients in the Italian Cohort of Individuals, NaA⁻ve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014. HIV Medicine, 2019, 20, 99-109.	2.2	19
7	The Association between Detected drug Resistance Mutations and CD4 ⁺ T-Cell Decline in HIV-Positive Individuals Maintained on a Failing Treatment Regimen. Antiviral Therapy, 2018, 23, 105-116.	1.0	3
8	Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort. HIV Clinical Trials, 2018, 19, 52-60.	2.0	6
9	Incidence of cancer and overall risk of mortality in individuals treated with raltegravirâ€based and nonâ€raltegravirâ€based combination antiretroviral therapy regimens. HIV Medicine, 2018, 19, 102-117.	2.2	6
10	HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients. PLoS ONE, 2018, 13, e0190302.	2.5	5
11	Plasma HIV-1 Tropism and the Risk of Short-Term Clinical Progression to AIDS or Death. PLoS ONE, 2017, 12, e0166613.	2.5	2
12	Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort. PLoS ONE, 2017, 12, e0177402.	2.5	15
13	Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study. PLoS ONE, 2017, 12, e0186638.	2.5	59
14	Proportion and factors associated with recent HIV infection in a cohort of patients seen for care in Italy over 1996-2014: Data from the ICONA Foundation Study cohort. PLoS ONE, 2017, 12, e0189045.	2.5	4
15	Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART. Journal of Antimicrobial Chemotherapy, 2016, 71, 2663-2669.	3.0	10
16	Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice. PLoS ONE, 2016, 11, e0160761.	2.5	5
17	Plasma levels of cytokines and chemokines and the risk of mortality in HIV-infected individuals. Aids, 2015, 29, 847-851.	2.2	42
18	Incidence and factors associated with the risk of sexually transmitted diseases in <scp>HIV</scp> â€infected people seen for care in <scp>I</scp> taly: data from the <scp>I</scp> cona <scp>F</scp> oundation cohort. HIV Medicine, 2015, 16, 412-420.	2.2	4

#	Article	IF	CITATIONS
19	Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing. Journal of Antimicrobial Chemotherapy, 2015, 70, 930-940.	3.0	102
20	Cytomegalovirus Coinfection Is Associated With an Increased Risk of Severe Non–AIDS-Defining Events in a Large Cohort of HIV-Infected Patients. Journal of Infectious Diseases, 2015, 211, 178-186.	4.0	146
21	Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort. Journal of the International AIDS Society, 2014, 17, 19825.	3.0	5
22	Durability of lopinavir/ritonavir dual-therapies in individuals with viral load <50 copies/mL in the observational setting. Journal of the International AIDS Society, 2014, 17, 19799.	3.0	1
23	Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice. Journal of the International AIDS Society, 2014, 17, 19571.	3.0	1
24	Plasma HIV-1 tropism and risk of short-term clinical progression to AIDS or death. Journal of the International AIDS Society, 2014, 17, 19685.	3.0	1
25	The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI [*] . HIV Medicine, 2012, 13, 62-72.	2.2	23
26	Resumption of HIV replication is associated with monocyte/macrophage derived cytokine and chemokine changes: results from a large international clinical trial. Aids, 2011, 25, 1207-1217.	2.2	40
27	Can Linear Regression Modeling Help Clinicians in the Interpretation of Genotypic Resistance Data? An Application to Derive a Lopinavir-Score. PLoS ONE, 2011, 6, e25665.	2.5	5
28	Relating protease inhibitor resistance at time of virological failure with drug exposure. Journal of the International AIDS Society, 2010, 13, P118.	3.0	0
29	Rate of Accumulation of Thymidine Analogue Mutations in Patients Continuing to Receive Virologically Failing Regimens Containing Zidovudine or Stavudine: Implications for Antiretroviral Therapy Programs in Resourceâ€Limited Settings. Journal of Infectious Diseases, 2009, 200, 687-697.	4.0	56
30	Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2009, 9, 409-417.	9.1	216
31	Initiatives for developing and comparing genotype interpretation systems: external validation of existing ruleâ€based interpretation systems for abacavir against virological response ^{â€} . HIV Medicine, 2008, 9, 27-40.	2.2	6
32	Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. Aids, 2008, 22, 2187-2198.	2.2	37
33	Modelled <i>in vivo</i> HIV Fitness under drug Selective Pressure and Estimated Genetic Barrier Towards Resistance are Predictive for Virological Response. Antiviral Therapy, 2008, 13, 399-408.	1.0	17
34	Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. Aids, 2007, 21, 721-732.	2.2	85
35	A Comparison between Abacavir and Efavirenz as the Third Drug Used in Combination with a Background Therapy Regimen of 2 Nucleoside Reverseâ€Transcriptase Inhibitors in Patients with Initially Suppressed Viral Loads. Journal of Infectious Diseases, 2006, 194, 20-28.	4.0	6
36	Impact of Lamivudine on the Risk of Liver-Related Death in 2,041 Hbsag- and HIV-Positive Individuals: Results from An Inter-Cohort Analysis. Antiviral Therapy, 2006, 11, 567-574.	1.0	38

#	Article	IF	CITATIONS
37	Lopinavir/Ritonavir or Efavirenz plus two Nucleoside Analogues as First-Line Antiretroviral Therapy: A Non-Randomized Comparison. Antiviral Therapy, 2006, 11, 609-618.	1.0	19
38	Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy. Antiviral Therapy, 2005, 10, 791-802.	1.0	20
39	Thymidine Analogue Mutation Profiles: Factors Associated with Acquiring Specific Profiles and their Impact on the Virological Response to Therapy. Antiviral Therapy, 2005, 10, 791-802.	1.0	55
40	The Management of Hepatitis B Virus/HIV-1 Co-Infected Patients Starting Their First Haart Regimen. Treating Two Infections for the Price of One Drug?. Antiviral Therapy, 2004, 9, 811-817.	1.0	11
41	Changes in viral load in people with virological failure who remain on the same HAART regimen. Antiviral Therapy, 2003, 8, 127-36.	1.0	9
42	Changes in Viral Load in People with Virological Failure who Remain on the Same Haart Regimen. Antiviral Therapy, 2003, 8, 127-136.	1.0	24
43	Virologic and Immunologic Response to Regimens Containing Nevirapine or Efavirenz in Combination with 2 Nucleoside Analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) Study. Journal of Infectious Diseases, 2002, 185, 1062-1069.	4.0	88
44	Impact of Mutations Conferring Reduced Susceptibility to Lamivudine on the Response to Antiretroviral Therapy. Antiviral Therapy, 2001, 6, 195-198.	1.0	5
45	HIV Drug Susceptibility and Treatment Response to Mega-Haart Regimen in Patients from the Frankfurt HIV Cohort. Antiviral Therapy, 2000, 5, 49-55.	1.0	52